IN2015DN02966A - - Google Patents

Download PDF

Info

Publication number
IN2015DN02966A
IN2015DN02966A IN2966DEN2015A IN2015DN02966A IN 2015DN02966 A IN2015DN02966 A IN 2015DN02966A IN 2966DEN2015 A IN2966DEN2015 A IN 2966DEN2015A IN 2015DN02966 A IN2015DN02966 A IN 2015DN02966A
Authority
IN
India
Prior art keywords
prevention
treatment
formula
dyslipidemia
hypercholesterolemia
Prior art date
Application number
Other languages
English (en)
Inventor
Takizawa Toshiaki
Yoshinaka Yasunobu
Original Assignee
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co filed Critical Kowa Co
Publication of IN2015DN02966A publication Critical patent/IN2015DN02966A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/423Oxazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN2966DEN2015 2012-09-27 2013-09-27 IN2015DN02966A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012214635 2012-09-27
PCT/JP2013/005756 WO2014050134A1 (ja) 2012-09-27 2013-09-27 脂質異常症治療剤

Publications (1)

Publication Number Publication Date
IN2015DN02966A true IN2015DN02966A (es) 2015-09-18

Family

ID=50387566

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2966DEN2015 IN2015DN02966A (es) 2012-09-27 2013-09-27

Country Status (21)

Country Link
US (4) US9572798B2 (es)
EP (1) EP2902025B1 (es)
JP (1) JP6238460B2 (es)
KR (1) KR102098032B1 (es)
CN (1) CN104640544B (es)
AU (1) AU2013321918B2 (es)
BR (1) BR112015006305B1 (es)
CA (1) CA2901650C (es)
EA (1) EA024873B1 (es)
ES (1) ES2752039T3 (es)
HK (1) HK1206620A1 (es)
IL (1) IL237981B (es)
IN (1) IN2015DN02966A (es)
MX (1) MX357446B (es)
MY (1) MY177686A (es)
PH (1) PH12015500471A1 (es)
PL (1) PL2902025T3 (es)
PT (1) PT2902025T (es)
SG (1) SG11201501740XA (es)
TW (1) TWI598098B (es)
WO (1) WO2014050134A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI691331B (zh) * 2014-09-26 2020-04-21 日商興和股份有限公司 脂質異常症治療劑
CN110809469A (zh) * 2017-06-30 2020-02-18 兴和株式会社 医药组合物
EP3646867A4 (en) * 2017-06-30 2021-03-24 Kowa Company, Ltd. PHARMACEUTICAL COMPOSITION
JPWO2019004447A1 (ja) * 2017-06-30 2020-04-30 興和株式会社 医薬組成物
WO2019004452A1 (ja) * 2017-06-30 2019-01-03 興和株式会社 医薬組成物
WO2019004453A1 (ja) * 2017-06-30 2019-01-03 興和株式会社 医薬品
US11419854B2 (en) 2017-06-30 2022-08-23 Kowa Company, Ltd. Medicament containing pemafibrate
JP7425603B2 (ja) * 2017-06-30 2024-01-31 興和株式会社 医薬組成物
JP7007379B2 (ja) * 2017-06-30 2022-02-10 興和株式会社 医薬組成物
US11446282B2 (en) 2017-12-21 2022-09-20 Kowa Company, Ltd. Methods of treating mixed dyslipidemia and hypertriglycertdemia
CA3085951C (en) * 2017-12-21 2022-10-11 Kowa Company, Ltd. Methods of treatment of hypertriglyceridemia
US20220096443A1 (en) * 2018-12-27 2022-03-31 Kowa Company, Ltd. Pharmaceutical composition

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100509058C (zh) 2001-01-26 2009-07-08 先灵公司 过氧化物酶体增殖物激活受体(ppar)活化剂和甾醇吸收抑制剂的组合药以及对于血管适应症的治疗
WO2003043997A1 (en) 2001-11-15 2003-05-30 Eli Lilly And Company Peroxisome proliferator activated receptor alpha agonists
US6987118B2 (en) 2003-05-21 2006-01-17 Pfizer Inc. Tetrahydroisoquinoline derivatives as PPAR-alpha activators
JPWO2005009942A1 (ja) 2003-07-28 2006-09-07 杏林製薬株式会社 光学活性置換フェニルプロピオン酸誘導体
BRPI0413991B8 (pt) * 2003-09-03 2021-05-25 Kowa Co composto ativador de ppar e composição farmacêutica contendo o mesmo
CN100425594C (zh) * 2003-09-03 2008-10-15 兴和株式会社 Ppar活性化化合物及含该化合物的医药组合物
DE102004016845A1 (de) 2004-04-07 2005-10-27 Bayer Healthcare Ag Phenylthioessigsäure-Derivate und ihre Verwendung
DE602005024836D1 (de) 2004-09-16 2010-12-30 Merck Sharp & Dohme Verbindungen zur behandlung von dyslipidämie und anderer lipidstörungen
TWI359810B (en) 2004-11-04 2012-03-11 Mitsubishi Tanabe Pharma Corp Carboxylic acid derivative containing thiazole rin
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
WO2007008529A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc Celullar cholesterol absorption modifiers
US7795291B2 (en) 2006-07-07 2010-09-14 Bristol-Myers Squibb Company Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
CN101583612A (zh) 2006-09-15 2009-11-18 先灵公司 治疗脂质代谢障碍的氮杂环丁酮衍生物
WO2008104875A1 (en) 2007-03-01 2008-09-04 Pfizer Products Inc. Oxazolidinones as cholesterol absorption inhibitors
TWI407955B (zh) 2007-03-29 2013-09-11 Kowa Co 高脂血症之預防及/或治療劑
WO2009047240A1 (en) 2007-10-09 2009-04-16 Smithkline Beecham Corporation Indole derivatives useful as ppar activators
DE102007061757A1 (de) 2007-12-20 2009-06-25 Bayer Healthcare Ag Substituierte 2-Phenylpyrimidin-5-carbonsäuren und ihre Verwendung

Also Published As

Publication number Publication date
EA024873B1 (ru) 2016-10-31
HK1206620A1 (en) 2016-01-15
CN104640544B (zh) 2017-05-03
AU2013321918B2 (en) 2018-05-10
JP6238460B2 (ja) 2017-11-29
CA2901650A1 (en) 2014-04-03
IL237981A0 (en) 2015-05-31
KR20150063035A (ko) 2015-06-08
PL2902025T3 (pl) 2020-03-31
AU2013321918A1 (en) 2015-04-23
MY177686A (en) 2020-09-23
KR102098032B1 (ko) 2020-04-07
PT2902025T (pt) 2019-11-04
CN104640544A (zh) 2015-05-20
US20190167645A1 (en) 2019-06-06
US9572798B2 (en) 2017-02-21
EA201590653A1 (ru) 2015-07-30
US9931321B2 (en) 2018-04-03
US11013722B2 (en) 2021-05-25
US10258609B2 (en) 2019-04-16
ES2752039T3 (es) 2020-04-02
MX357446B (es) 2018-07-10
EP2902025A1 (en) 2015-08-05
IL237981B (en) 2020-05-31
US20180185337A1 (en) 2018-07-05
MX2015003705A (es) 2015-06-10
US20170112811A1 (en) 2017-04-27
EP2902025B1 (en) 2019-08-07
TW201417811A (zh) 2014-05-16
WO2014050134A1 (ja) 2014-04-03
EP2902025A4 (en) 2016-03-02
TWI598098B (zh) 2017-09-11
US20150196538A1 (en) 2015-07-16
JPWO2014050134A1 (ja) 2016-08-22
BR112015006305A2 (pt) 2017-07-04
SG11201501740XA (en) 2015-04-29
CA2901650C (en) 2021-05-04
PH12015500471B1 (en) 2015-04-20
PH12015500471A1 (en) 2015-04-20
BR112015006305B1 (pt) 2020-11-17

Similar Documents

Publication Publication Date Title
IN2015DN02966A (es)
PH12017501306A1 (en) Inhibitors of histone demethylases
PH12016502581A1 (en) TrK-INHIBITING COMPOUND
EA201690283A1 (ru) Композиции и терапевтические способы для ускоренного регресса бляшки
BR112015022643A2 (pt) inibidores diidro-pirrolpiridinona
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
CL2014002518A1 (es) Compuestos derivados heterociclicos nitrogenados, inhibidores de la bace-1 o de la bace-2; composicion farmaceutica que los comprende; combinacion farmaceutica; su uso en el tratamiento o prevencion de la enfermedad de alzheimer o un deterioro cognitivo leve.
BR112014021531A8 (pt) composto, composição farmacêutica e usos dos mesmos
EA201000886A1 (ru) Органические соединения
BR112015005117A2 (pt) métodos de tratamento da doença de alzheimer e suas composições farmacêuticas
BR112014031068A2 (pt) derivados piridinona e piridazinona
EA201200098A1 (ru) Конденсированные имидазолы и содержащие их композиции, предназначенные для лечения паразитарных заболеваний, таких как, например, малярия
UA113538C2 (xx) Фторметил-5,6-дигідро-4h-$1,3]оксазини
WO2013040227A3 (en) Therapeutic compounds
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
EA201690284A1 (ru) Композиции и терапевтические способы для ускоренного регресса бляшки
MX2021012096A (es) Compuestos de indenilo, composiciones farmaceuticas y usos medicos del mismo.
CL2014003607A1 (es) Compuestos derivados de benzodioxol, inhibidores de la acetilcolinesterasa; metodo de preparacion; compuestos intermediarios; composicion farmaceutica; y uso en la prevencion o el tratamiento de la enfermedad de alzheimer.
UA113975C2 (xx) Застосування фармацевтичної композиції або добавки, яка містить фосфатидилсерин і куркумін (варіанти)
BR112014004437A8 (pt) composto, composição farmacêutica, preparação farmacêutica, processo para o preparo de um composto de fórmula, intermediário, métodos para a prevenção ou tratamento de malária e para inativação de infecção parasítica em uma célula.
BR112015006220A2 (pt) agentes antibacterianos de tetrahidroquinolina tricíclica
NZ707832A (en) 2-pyridone compound
WO2015181837A3 (en) Novel compounds as anti-tubercular agents
EA201600411A1 (ru) Производные пиперидина для применения при лечении или профилактики психиатрических и неврологических состояний
BR112014009217A2 (pt) antibacterianos à base de fenicol